Ownership and insider activity for Enlivex Therapeutics Ltd. (ENLV): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis.
Price
| Price | $0.81 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | IL |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-03-18 | Hershkovitz Oren | |||
| 2023-11-16 | Hershkovitz Oren | 150,000 | $1.2M | |
| 2025-11-24 | Hershkovitz Oren | 60,000 | $320K | |
| 2026-03-18 | Shlosberger Shachar | |||
| 2021-03-07 | Shlosberger Shachar | 1,452 | $4K | |
| 2021-12-12 | Shlosberger Shachar | 1,452 | $9K | |
| 2024-03-30 | Shlosberger Shachar | 5,000 | $23K | |
| 2022-12-10 | Shlosberger Shachar | 1,452 | $15K | |
| 2025-11-24 | Shlosberger Shachar | 10,000 | $32K | |
| 2025-11-24 | Shlosberger Shachar | 7,500 | $40K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.9M | $3.5M | $9.7M | $3.9M | $5.7M | $11.2M | $49.9M | $813000 | $3.3M | $2.0M |
| Short-term Investments | $3.0M | 0 | $40000 | $8.1M | $30.0M | $72.9M | $299000 | $26.5M | $20.2M | $3.9M |
| Receivables | $52000 | $28000 | $213000 | $2.4M | $1.2M | $1.1M | $647000 | $229000 | $1.3M | $235000 |
| Inventory | 0 | 0 | 0 | $1.5M | 0 | 0 | $1.2M | 0 | 0 | 0 |
| Total Current Assets | $10.5M | $3.6M | $10.3M | $16.4M | $38.1M | $86.4M | $52.3M | $33.8M | $26.0M | $1.74B |
| Property, Plant & Equipment | $71000 | $388 | $685000 | $1.1M | $2.1M | $8.2M | $14.9M | $2.6M | $1.2M | $938000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $410000 | 0 | 0 | 0 | 0 | 0 | $582.5M |
| Total Assets | $10.6M | $3.6M | $11.0M | $17.6M | $40.4M | $95.1M | $67.6M | $36.8M | $27.7M | $2.33B |
| Accounts Payable | $32000 | $19000 | $173000 | $316000 | $463000 | $878000 | $1.9M | $827000 | $811000 | $3.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $653000 | 0 | 0 | 0 |
| Total Current Liabilities | $1.9M | $460000 | $1.1M | $6.0M | $4.4M | $4.7M | $6.6M | $6.1M | $3.8M | $9.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.9M | $460000 | $1.3M | $6.3M | $4.9M | $10.1M | $10.8M | $6.7M | $4.1M | $392.1M |
| Retained Earnings | -$39.8M | -$45.8M | -$16.3M | -$25.7M | -$37.5M | -$52.0M | -$83.0M | -$112.1M | -$127.1M | $1.11B |
| Total Equity | $8.7M | $3.2M | $9.7M | $11.3M | $35.5M | $85.0M | $56.8M | $30.1M | $23.6M | $1.93B |
| Total Debt | 0 | 0 | 0 | $123000 | $203000 | $6.0M | $4.8M | $1.0M | $534000 | $641000 |
| Net Debt | -$9.9M | -$3.5M | -$9.8M | -$11.9M | -$35.5M | -$78.1M | -$45.4M | -$26.3M | -$23.1M | -$5.2M |
| Working Capital | $8.6M | $3.2M | $9.1M | $10.4M | $33.7M | $81.7M | $45.7M | $27.7M | $22.2M | $1.73B |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 193.24 |
Profitability
| Return on Equity | 248.08% |
| Return on Invested Capital | -0.49% |
| Return on Assets | 53.10% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLGN · CVKD · GDTC · LSTA · MTVA · NCNA · NRSN
Explore sector: Healthcare · Biotechnology
More sections of ENLV: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks